Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Genitourinary (Prostate) Cancer

Type: Oral Abstract Session

Time: Saturday June 3, 1:15 PM to 4:15 PM

Location: Hall B1

Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC).

Sub-category:
Biomarkers/Epidemiology/Outcomes

Category:
Genitourinary (Prostate) Cancer

Meeting:
2017 ASCO Annual Meeting

Abstract No:
5006

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 5006)

Author(s): Andrew J. Armstrong, Lars Edenbrandt, Eva Bondesson, Aseem Anand, Orjan Nordle, Michael Anthony Carducci, Michael J. Morris; Division of Medical Oncology and Urology, Duke Cancer Institute, Duke University, Durham, NC; Sahlgrenska University Hospital, Gothenburg, Sweden; EXINI Diagnostics, Lund, Sweden; Memorial Sloan-Kettering Cancer Center, New York, NY; Nordle Biostatistical Consultancy, Rydebäck, Sweden; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Memorial Sloan-Kettering Cancer Center and Weil Cornell Medical College, New York, NY

Abstract Disclosures

Abstract:

Background: Quantitative measures of metastatic bone disease are needed in men with mCRPC. We recently demonstrated the validity/reproducibility of a computational approach to bone scan imaging that employs artificial intelligence called the automated BSI (aBSI), which quantifies the percent of skeletal mass involved by cancer. We aimed to extend the prognostic validation of aBSI in a multinational prospective phase 3 clinical study of men with bone-metastatic CRPC. Methods: Whole-body bone scans were acquired at screening in a placebo-controlled phase 3 trial of men with mCRPC and bone metastases and treated with tasquinimod/placebo (n = 1,245). The prospective aBSI biomarker analysis plan was locked in Sept 2014 prior to treatment unblinding. All scans generated at 241 trial sites in 37 countries were assessed for image quality and analyzed using the EXINI boneBSI v.2 software and were blindly associated with outcomes. Baseline aBSI was evaluated for its independent prognostic association with overall survival (OS), radiographic progression-free survival (rPFS), and symptomatic skeletal related events (SSEs). Results: The aBSI-population (721 pts) was representative of the entire trial population based on patient characteristics at screening and OS outcomes. Median aBSI was 1.07 (SE 0.05). The aBSI-population was divided into quartiles (n = 180-181) with aBSI-levels of 0 - 0.3 (Q1); > 0.3 - 1.1 (Q2); > 1.1 - 4.0 (Q3); and > 4.0 (Q4) and median OS ranging from 35 months (Q1) to 13 mo (Q4) (p < 0.0001). Baseline aBSI was significantly associated with OS (HR 1.2 per doubling of BSI; p < 0.0001) and remained independently associated with OS after adjustment for treatment, PSA, CRP, LDH and albumin. Baseline aBSI was also strongly associated with rPFS (p = 0.0005), time to symptomatic progression (p < 0.0001), and time to SSE (p = 0.001). Conclusions: This analysis represents the first phase 3 evaluation of aBSI as a clinically validated prognostic biomarker for OS, rPFS, and SSEs in men with bone-metastatic CRPC, providing independent prognostic information over commonly measured clinical characteristics. Clinical trial information: NCT01234311

 
Other Abstracts in this Sub-Category:

 

1. Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk.

Meeting: 2017 ASCO Annual Meeting Abstract No: 5000 First Author: Daniel Eidelberg Spratt
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes

 

2. Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials.

Meeting: 2017 ASCO Annual Meeting Abstract No: 5007 First Author: Glenn Heller
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes

 

3. Need for re-evaluation of current guidelines based on results from germline genetic testing in prostate cancer.

Meeting: 2017 ASCO Annual Meeting Abstract No: 5009 First Author: Piper L.W. Nicolosi
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes

 

More...